TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34970330

Group type: EXPERIMENTAL
Intervention: Aerosolized glucocorticoid
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Aerosolized glucocorticoid combined with bronchodilator
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 145
Study: 35849397

Group type: EXPERIMENTAL
Intervention: RealRisks decision aid for patients and the Breast Cancer Risk Navigation Tool decision support for clinicians
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 187
Study: 33293362

Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 262
Study: 36278221

Group type: EXPERIMENTAL
Intervention: H2-O2 group (inhaled H2-O2 mixture 66% H2/33% O2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air group (inhaled placebo air)
Number of subjects: 60
Study: 34431518

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 326

Group type: COMPARATOR
Intervention: EWL ?5%
Number of subjects: 326

Group type: COMPARATOR
Intervention: EWL <5%
Number of subjects: 326
Study: 33567701

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (Lactica-seibacillus paracasei strain Shirota and Bifidobacterium breve strain Yakult, and galactooligosaccharides) for 24 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 36226902

Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 0
Study: 32188366

Group type: EXPERIMENTAL
Intervention: 50,000IU vitamin D3 per week
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 80,000IU vitamin D3 per week
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 110,000IU vitamin D3 per week
Number of subjects: 27
Study: 32062731

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 1852

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (in cervical adenocarcinoma or adenosquamous carcinoma)
Number of subjects: 1852

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (in cervical adenocarcinoma or adenosquamous carcinoma)
Number of subjects: 1852
Study: 36334697

Group type: EXPERIMENTAL
Intervention: Vitamin D administration
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 33522881

Group type: EXPERIMENTAL
Intervention: ICU triage policies that promote population health outcomes and mitigate health inequities.
Number of subjects: 0
Study: 32046418

Group type: EXPERIMENTAL
Intervention: Single-dose secnidazole 2 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34055971

Group type: EXPERIMENTAL
Intervention: Nomogram based on predictive variables (age, site, grade, tumor size, histology, stage, use of surgery, radiotherapy, or chemotherapy)
Number of subjects: 813
Study: 35705975

Group type: EXPERIMENTAL
Intervention: iSTART web-app intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 600
Study: 33106479

Group type: EXPERIMENTAL
Intervention: Maternal genetic risk score (GRS) associated with offspring birthweight
Number of subjects: 26057

Group type: EXPERIMENTAL
Intervention: Offspring genetic risk score (GRS)
Number of subjects: 26057
Study: 33394543

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Non-metformin users
Number of subjects: 1745
Study: 32032356

Group type: EXPERIMENTAL
Intervention: Training programme based on the ICF framework
Number of subjects: 203

Group type: COMPARATOR
Intervention: Short talk and a booklet on interprofessional practice (control)
Number of subjects: 203
Study: 36320143

Group type: EXPERIMENTAL
Intervention: Low-dose temsirolimus (0.1 mg/mL)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose temsirolimus (0.4 mg/mL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Temsirolimus (combined low and high dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 61
Study: 34173042

Group type: EXPERIMENTAL
Intervention: Gastroschisis (girls)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Gastroschisis (boys)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Omphalocele
Number of subjects: 328
Study: 32723109

Group type: EXPERIMENTAL
Intervention: 32 G × 4 mm pen needle (PN)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Thinner comparator pen needles (33–34 G × 3.5–4 mm PNs and one 34 G × 4 mm PN)
Number of subjects: 209
Study: 35643358

Group type: EXPERIMENTAL
Intervention: Casein peptide (TMP, n = 15)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Casein (TMC, n = 16)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Indigestible dextrin (TMF, n = 16)
Number of subjects: 47
Study: 32212254

Group type: EXPERIMENTAL
Intervention: Early rehabilitation combined with virtual reality (VR) training (15 min, two times a day for 5 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Early rehabilitation alone
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Early rehabilitation combined with virtual reality (VR) training
Number of subjects: 152
Study: 36004439

Group type: EXPERIMENTAL
Intervention: Dynamic lighting installation
Number of subjects: 54
Study: 34624421

Group type: EXPERIMENTAL
Intervention: Conventional resin cement (RelyX Ultimate) with universal adhesive (Scotchbond Universal) without selective enamel etching (SB-E)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional resin cement (RelyX Ultimate) with universal adhesive (Scotchbond Universal) with selective enamel etching (SB+E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX Unicem 2; RXU)
Number of subjects: 50
Study: 34601619

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration-adsorption (CPFA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 33262767

Group type: EXPERIMENTAL
Intervention: Patients with CHS (spontaneous clearance)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with CHC (chronic infection)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with CHC
Number of subjects: 86

Group type: COMPARATOR
Intervention: Patients
Number of subjects: 86
Study: 35470243

Group type: EXPERIMENTAL
Intervention: G‐POEM
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 41
Study: 34688948

Group type: COMPARATOR
Intervention: T-cell receptor beta chain (TCRβ) features in COVID-19 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnostic model based on TCRβ clones
Number of subjects: 0
Study: 33638879

Group type: COMPARATOR
Intervention: Continuous Aerobic Exercise Training (CAET)
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 47
Study: 36401364

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel (APRG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 72
Study: 33598778

Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid gel + open flap debridement (OFD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: open flap debridement (OFD) + placebo
Number of subjects: 20
Study: 32176093

Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES) treatment on 3 consecutive days in addition to best supportive care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sham treatment on 3 consecutive days in addition to best supportive care
Number of subjects: 400
Study: 34382725

Group type: EXPERIMENTAL
Intervention: Post-ICU patients
Number of subjects: 523
Study: 33453044

Group type: EXPERIMENTAL
Intervention: Emotional and Behavioral Health‐Crisis Response and Prevention (EBH‐CRP) intervention
Number of subjects: 40
Study: 33174935

Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical-case-based discussion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online tutorial
Number of subjects: 0
Study: 34524009

Group type: EXPERIMENTAL
Intervention: Telemetric continuous glucose monitoring (CGM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional point-of-care (POC) glucose testing + blinded CGM
Number of subjects: 64
Study: 32585837

Group type: EXPERIMENTAL
Intervention: Whey protein isolate + bioactives (WPI + BIO) capsules containing omega‐3 fatty acids, rutin, and curcumin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Carbohydrate + placebo capsules (CHO)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Whey protein isolate + bioactives (WPI + BIO)
Number of subjects: 37
Study: 35624421

Group type: EXPERIMENTAL
Intervention: Stakeholder engagement process including community meetings and qualitative interviews with new fathers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Community Advisory Board and qualitative interviews
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Engagement of fathers and community leaders
Number of subjects: 16
Study: 34585449

Group type: EXPERIMENTAL
Intervention: Lepidium meyenii (yellow maca)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32675601

Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 253

Group type: COMPARATOR
Intervention: Arthrodesis (ACD and ACDF combined)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 253
Study: 35671100

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with ALK Alutard Birch and Grass 1000 SQ‐U, three intralymphatic injections with one-month intervals
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 35655147

Group type: EXPERIMENTAL
Intervention: Proprioceptive and tactile stimulation vest
Number of subjects: 10
Study: 32237279

Group type: EXPERIMENTAL
Intervention: In-house general practitioners present in residential aged care facilities
Number of subjects: 15
Study: 33979488

Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg) every 4 weeks for 52 weeks
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg)
Number of subjects: 1061
Study: 33187565

Group type: EXPERIMENTAL
Intervention: Self-kinematic training program using virtual reality, 20 min/week for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 34813673

Group type: EXPERIMENTAL
Intervention: Cenobamate (200 mg/day, median modal dose)
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Cenobamate (≥100 mg/day)
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 1844
Study: 32445670

Group type: EXPERIMENTAL
Intervention: Subcutaneous C1‐INH (40 IU/kg or 60 IU/kg) administered twice weekly for 52 to 140 weeks
Number of subjects: 10
Study: 36075589

Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture in addition to rt-PA intravenous thrombolysis
Number of subjects: 142

Group type: COMPARATOR
Intervention: Western medication group (rt-PA intravenous thrombolysis only)
Number of subjects: 142
Study: 33884661

Group type: EXPERIMENTAL
Intervention: Neem
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 50
Study: 33284201

Group type: EXPERIMENTAL
Intervention: Early commencement of parenteral nutrition immediately after birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commencement of parenteral nutrition within 24 hours of admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delaying parenteral nutrition to day 8 of admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very high doses of amino acids (>3.5 g/kg/day) immediately after birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commencing parenteral nutrition on the first day of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition after 72 hours if enteral feeds are not tolerated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoiding parenteral nutrition within 24 hours of admission
Number of subjects: 0
Study: 32502443

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) plus Bevacizumab (15 mg/kg) every 3 weeks
Number of subjects: 223

Group type: COMPARATOR
Intervention: Atezolizumab alone
Number of subjects: 223
Study: 35536730

Group type: EXPERIMENTAL
Intervention: Intraoperative pectoral nerve block (PECS) with 10 ml of 0.5% bupivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ultrasound guided thoracic paravertebral block (TPV) with 25 ml of 0.25% bupivacaine at T3 level
Number of subjects: 41
Study: 33715994

Group type: EXPERIMENTAL
Intervention: Mannitol 400 mg BID
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control (mannitol 50 mg)
Number of subjects: 423
Study: 36084912

Group type: COMPARATOR
Intervention: Standard cycling-off setting (expiratory trigger sensitivity set at 25% of peak inspiratory flow)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Expert optimisation of cycling-off settings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Automated cycling-off settings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Expert optimisation
Number of subjects: 15
Study: 32054899

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.33% ropivacaine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.2% and 0.5% ropivacaine
Number of subjects: 85
Study: 35553959

Group type: EXPERIMENTAL
Intervention: Metformin treatment for three days
Number of subjects: 44
Study: 32899094

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% + dexmedetomidine 0.5 μg/mL (RD1 group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08% + dexmedetomidine 0.5 μg/mL (RD2 group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% + sufentanil 0.5 μg/mL (RS1 group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08% + sufentanil 0.5 μg/mL (RS2 group)
Number of subjects: 160
Study: 32147870

Group type: EXPERIMENTAL
Intervention: Personalized syncope decision aid (SynDA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 33404812

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (109 CFU/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32339499

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (3 mcg/kg loading dose followed by 16.9 ng/kg/min infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ghrelin receptor blocker (PF-5190457)
Number of subjects: 0
Study: 35366660

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 149
Study: 33546069

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg 5 minutes after anesthesia induction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 32048288

Group type: EXPERIMENTAL
Intervention: Fermented soybean meal (FSBM) biscuits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soybean meal (SBM) biscuits
Number of subjects: 0
Study: 35209924

Group type: EXPERIMENTAL
Intervention: High eGFR group
Number of subjects: 2092

Group type: COMPARATOR
Intervention: Low eGFR group
Number of subjects: 2092
Study: 33473242

Group type: EXPERIMENTAL
Intervention: Commiphora molmol (myrrh) mouthwash used twice a day for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline mouthwash used twice a day for 7 days
Number of subjects: 40
Study: 33926138

Group type: EXPERIMENTAL
Intervention: Leeds Pathology Protocol (LEEPP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional method (group B)
Number of subjects: 168
Study: 32200817

Group type: EXPERIMENTAL
Intervention: 20 Gy of external beam therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 42
Study: 35450936

Group type: EXPERIMENTAL
Intervention: Facilitated implementation of clinical practice guidelines (CPG) for 6 months (n=18 wards)
Number of subjects: 10383

Group type: COMPARATOR
Intervention: Standard clinical practice guideline dissemination (n=18 wards)
Number of subjects: 10383
Study: 32426989

Group type: EXPERIMENTAL
Intervention: Simulation-based education plus lecture-based education
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lecture-based education
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Simulation-based education
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lecture-based education alone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 101
Study: 32787944

Group type: EXPERIMENTAL
Intervention: Training modules for direct care staff on recognition, management, and reporting of R-REM delivered on-site after baseline data collection.
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Usual care (control group) in assisted living residences without the intervention.
Number of subjects: 1050
Study: 35320163

Group type: EXPERIMENTAL
Intervention: Mulligan technique
Number of subjects: 78

Group type: COMPARATOR
Intervention: muscle energy technique
Number of subjects: 78
Study: 32313941

Group type: EXPERIMENTAL
Intervention: Lateral flow urine lipoarabinomannan assay (LF‐LAM)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Reference standard of positive mycobacterial culture (sputum or urine)
Number of subjects: 1505
Study: 33175641

Group type: EXPERIMENTAL
Intervention: Vaccination logistic management training
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Good knowledge and attitude towards management systems
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Professional experience and gender
Number of subjects: 180
Study: 32444230

Group type: EXPERIMENTAL
Intervention: Epinephrine mixed with ropivacaine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (ropivacaine without epinephrine)
Number of subjects: 89
Study: 36088783

Group type: EXPERIMENTAL
Intervention: Advice in combination with blood flow restriction training (BFRT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Traditional high intensity training (HIT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 59
Study: 34143971

Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 (200 mg every 3 weeks and 15 mg/kg every 3 weeks respectively)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305
Number of subjects: 595

Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 595
Study: 35339706

Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted lower trapezius transfer (aLTT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Arthroscopic-assisted latissimus dorsi transfer (aLDT)
Number of subjects: 90
Study: 34170062

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Individualized medical therapy
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2566
Study: 35939288

Group type: EXPERIMENTAL
Intervention: AI-CBT-CP
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard CBT-CP
Number of subjects: 278
Study: 32773515

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control
Number of subjects: 407
Study: 34345902

Group type: EXPERIMENTAL
Intervention: Pregnant women with SLE
Number of subjects: 118

Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 118
Study: 32196506

Group type: COMPARATOR
Intervention: Single dose of praziquantel (40 mg/kg)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Four repeated doses of praziquantel (40 mg/kg) administered at two-week intervals
Number of subjects: 153
Study: 34693771

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) co-implantation
Number of subjects: 37

Group type: COMPARATOR
Intervention: No capsular tension ring (CTR) co-implantation (Control)
Number of subjects: 37
Study: 32906032

Group type: EXPERIMENTAL
Intervention: Mycophenolate (MMF)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study: 35209934

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) capsules taken orally on day 1, day 7, and day 14
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsules taken orally on day 1, day 7, and day 14
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) capsules
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 120
Study: 32917259

Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation for 48 hours with settings starting at pre-existing PEEP, tidal volume of 6 ml/kg lean body mass, and respiratory rate to maintain arterial pH above 7.2.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ventilation adjusted by the attending ICU team according to lung-protective ventilation strategy.
Number of subjects: 20
Study: 35032379

Group type: COMPARATOR
Intervention: Lidocaine 2% and Bupivacaine 0.25% (max 2mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and Bupivacaine 0.25% with 25 μg of Epinephrine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% and Bupivacaine 0.25% with 2mg Dexamethasone
Number of subjects: 63